Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective
نویسندگان
چکیده
منابع مشابه
Steroid-Refractory Acute GVHD: Predictors and Outcomes
Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, with mortality rates in excess of 90%. We sought to identify a subgroup of patients less likely to benefit from initial therapy with corticosteroids as well as the impact of response on day 14 on outcome. Retrospective evaluation was performed of patients with biopsy-proven aGVHD treated with cortic...
متن کاملSuccessful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
Fig. 1. Platelet count after alemtuzumab treatment. Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab TO THE EDITOR: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by an isolated decrease in platelet count. There are multiple mechanisms underlying this disease, including autoantibodies against platelet membrane proteins and impaired p...
متن کاملLow-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
Treatment of autoimmune cytopenias remains unsatisfactory for patients refractory to first-line management. We evaluated the safety and efficacy of low-dose rituximab plus alemtuzumab in patients with steroid-refractory autoimmune hemolytic anemia and immune thrombocytopenic purpura. Nineteen of 21 included patients were assessable for response (11 with immune thrombocytopenic purpura, 8 with a...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating...
متن کاملA pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 2010
ISSN: 0268-3369,1476-5365
DOI: 10.1038/bmt.2010.68